Opioid Use Disorder (OUD) Market Forecasts to 2028 – Global Analysis By Drug Class (Methadone, Naltrexone and Buprenorphine), Distribution Channel (Retail Pharmacies & Stores, Hospitals Pharmacies and Online Pharmacies), Route of Administration (Parentera

Opioid Use Disorder (OUD) Market Forecasts to 2028 – Global Analysis By Drug Class (Methadone, Naltrexone and Buprenorphine), Distribution Channel (Retail Pharmacies & Stores, Hospitals Pharmacies and Online Pharmacies), Route of Administration (Parenteral and Oral), Age group (19 to 39, 40 to 59 and Age 60 and over), and By Geography

According tStratistics MRC, the Global Opioid Use Disorder (OUD) Market is accounted for $3.17 billion in 2022 and is expected treach $6.79 billion by 2028 growing at a CAGR of 13.5% during the forecast period. Opioids are a class of medications that alsrelax muscles, lessen pain, and ease stress. Ttreat moderate tsevere pain, doctors often prescribe drugs like hydrocodone, oxycodone, codeine, fentanyl, methadone, morphine, and other prescription opioids. It involves functional alterations tbrain circuits associated tmotivation, stress, self-control, and decision-making, and because those changes may persist for a long time after drug use has stopped, it is recognised as a brain condition.

Market Dynamics:

Driver:

Growing focus of government & non-government institutions tsupport expansion

The expansion of the business is being fuelled in part by the growing involvement of governmental and non-governmental organisations in raising awareness of opioid overdose and associated consequences. Several groups have expanded their efforts tcombat the issue as a result of the sharp rise in the number of opioid addicts. In order thelp patients and decrease the effects of opioid dependence, many countries have increased their efforts. For instance, Health and Human Services (HHS) announced financing for substance use treatment and prevention programmes in order tincrease access tmedication-assisted treatment for opioid use disorder and curb prescription drug abuse. It is predicted that similar programmes would motivate more people with opioid-related problems tseek treatment.

Restraint:

Adverse effects of OUD drugs

The market is expected texperience challenges throughout the forecast period due tthe negative effects of the medications used ttreat opioid addiction. These medications frequently cause muscle aches, nausea, vomiting, diarrhoea, bone or joint pain, respiratory problems, bladder pain, constipation, and cramping in the abdomen. In addition, in extreme instances of a medication reaction, the patient may alsexperience depression and other psychological issues. The U.S. FDA issued a warning due tthe hazards involved with these medications, which has a negative effect on the drug class and decreases the use of medications for this type of treatment.

Opportunity:

Increasing consideration of buprenorphine patches

An increase in demand for buprenorphine patch treatments has lately been observed in the market. These patches are regarded as an effective medication for the treatment of opioid use disorders. Transdermal patches have a number of traditional, self-administered benefits, including an easier drug administration mechanism and less pain. Also, these transdermal patches might be a viable substitute for patients whneed 24/7 opioid medication for opioid use disorder. Also, it is predicted that during the forecast period, a growing number of new patients will contribute tthe growth of the global market for opioid use disorder (OUD).

Threat:

Effects withdrawal syndrome

Withdrawal syndrome, which develops when repeated exposure ta pharmaceutical stimulus is stopped, is linked tdependency. Patients should be warned not tstop using long-term opioids without first lowering their dosage. Substance use disorder's subcategory of dependency can show physical, psychological, or both signs and symptoms. Regardless of the type of opioid used, withdrawal symptoms usually begin around the time of dependence. The main issue with opioid use disorder is withdrawal. When compared tmethadone, withdrawal from heroin might start as quickly as five hours following the last dose. Withdrawal symptoms that last for days or weeks are referred tas prolonged abstinence syndrome.

Covid-19 Impact

Due tdemand, the coronavirus pandemic has a variety of effects on the pharmaceutical business, ranging from favourable tunfavourable. Because fewer people are visiting healthcare institutions like hospitals and clinics, there has been a detrimental effect on the demand for some medications. Furthermore, a handful of governments have implemented a rigorous nationwide lockdown in an effort treduce the number of coronavirus cases. This has caused the flow of patients between hospital settings tdrastically decrease. Moreover, the cancellation or delay of unnecessary medical treatments has had a detrimental effect on market expansion. However, throughout the pandemic, well-known companies operating in the market for opioid use disorders, including Indivior PLC, saw a general reduction in their product revenues. As a result of COVID-19-related disruptions including lockdowns, transportation problems, and others, sales have fallen down quickly. Thus, it is anticipated that the market for opioid use disorders will suffer a setback.

The buprenorphine segment is expected tbe the largest during the forecast period

The buprenorphine segment is estimated thave a lucrative growth. The most frequently recommended medications for OUD are buprenorphine/naloxone sublingual pills, buprenorphine sublingual tablets, and brand-name Suboxone. Because tits outstanding clinical profile, Suboxone Film is the medication that doctors most frequently prescribe in the OUD market. The high acceptance of this medicine can be due ta number of variables, including its good formulary coverage, high efficacy in controlling addiction, low potential for abuse, and very minor adverse effects.

The parenteral segment is expected thave the highest CAGR during the forecast period

The parenteral segment is anticipated twitness the fastest CAGR growth during the forecast period, due tthe availability of several OUD medications in parenteral form and a range of dosages. As a result, this method of drug administration continues trule the world market.

Region with highest share:

Asia Pacific is projected thold the largest market share during the forecast period owing tincreasing awareness amongst the general population regarding OUD. Additionally, the substantial patient population base and the increasing healthcare spending in the region are likely tfavour the growth of the market in the region.

Region with highest CAGR:

North America is projected thave the highest CAGR over the forecast period. One of the major drivers behind North America's largest market share is the opioid epidemic that has ravaged the United States and Canada due tthe governments are implementing a number of initiatives. For instance, the American government started a public awareness campaign tfight opioid addiction. Throughout the course of the projected year, new medications are alsanticipated tenter the U.S. market, including Braeburn's CAM-2038-additional buprenorphine subcutaneous formulation for regular monthly injection.

Key players in the market

Some of the key players profiled in the Opioid Use Disorder (OUD) Market include Alkermes, Titan Pharmaceuticals, Inc, Hikma Pharmaceuticals PLC, Indivior PLC, Mallinckrodt Pharmaceuticals, Camurus, OrexAB, Viatris Inc, BioDelivery Sciences International Inc., Teva Pharmaceuticals Usa, Inc, Mylan, Azanta, Braeburn, Chiesi Pharmaceuticals, DiaMNarcotics, MaynePharma Group, Knight Therapeutics, Dr. Reddy's Laboratories, Collegium Pharmaceutical, Inc and Buvidal.

Key Developments:

In March 2022, Collegium Pharmaceutical, Inc. announced that it had completed the acquisition of BioDelivery Sciences International Inc.

In June 2020, Titan Pharmaceuticals, Inc. entered inta partnership with Indegene testablish a multichannel digital marketing program throughout the U.S. and further increase their competence in providing Probuphine implant 2016 for opioid addiction patients.

In February 2021, OrexAB announced its collaboration with ApexB.iand Magellan Rx Management tfurther research the use of Modia. This product is a digital therapeutic designed for patients with Opioid Use Disorder.

In December 2020, OrexAB entered intan exclusive agreement with Accord Healthcare for the commercialization of ZUBSOLV and naloxone sublingual tablets in Europe.

In February 2019, Dr. Reddy's Laboratories announced the re-launch of its buprenorphine and naloxone sublingual film after the company received a favourable ruling in patent litigation.

Drug Classes Covered:
• Methadone
• Naltrexone
• Buprenorphine

Distribution Channels Covered:
• Retail Pharmacies & Stores
• Hospitals Pharmacies
• Online Pharmacies

Route of Administrations Covered:
• Parenteral
• Oral

Age groups Covered:
• 19 t39
• 40 t59
• Age 60 and over

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements